Calidi Biotherapeutics (CLDI) Income from Continuing Operations (2022 - 2025)
Calidi Biotherapeutics' quarterly Income from Continuing Operations came in at 4059000.0 in Q4 2025, up 2.15% year-on-year from 3973738.97 in Q4 2024, and up 21.66% quarter-over-quarter from 5181000.0 in Q3 2025.
Calidi Biotherapeutics has reported Income from Continuing Operations for 4 years, with the latest figure at 4059000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 2.15% year-over-year to 4059000.0; the trailing twelve-month figure through Dec 2025 stood at 20063000.0 (up 9.66% YoY), and the FY2025 full-year result was 20063000.0, up 9.66% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 4059000.0, up from 5181000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4161210.0 in Q2 2022, with the low at 12501000.0 in Q2 2023.
- Average Income from Continuing Operations over 4 years is 4936787.31, with a median of 5267500.0 recorded in 2022.
- Peak annual rise in Income from Continuing Operations reached 62.2% in 2023, while the deepest fall reached 541.94% in 2023.
- Tracing CLDI's Income from Continuing Operations over 4 years: stood at 7770000.0 in 2022, then slipped by 5.91% to 8229000.0 in 2023, then soared by 49.59% to 4148000.0 in 2024, then climbed by 2.15% to 4059000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4059000.0 (Q4 2025), 5181000.0 (Q3 2025), and 5761000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.06 Mn |
| Sep 30, 2025 | -5.18 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Sep 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -7.23 Mn |
| Dec 31, 2023 | -8.23 Mn |
| Sep 30, 2023 | -2.02 Mn |
| Jun 30, 2023 | -12.50 Mn |
| Mar 31, 2023 | -6.46 Mn |
| Dec 31, 2022 | -7.77 Mn |
| Sep 30, 2022 | -5.35 Mn |
| Jun 30, 2022 | 4.16 Mn |
| Mar 31, 2022 | 1.46 Mn |